Pharma BD Deal Intelligence
Sanofi SA / Amunix Pharmaceuticals Inc.
2021 · Acquisition/Merger · $1.2B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
76
Worked — the deal delivered on its rationale.
Sanofi acquired Amunix Pharmaceuticals and its XTEN technology platform for T-cell engagers and pro-cytokine therapeutics in oncology.
Key facts
- Announced Dec 21, 2021
- Closed Feb 08, 2022
- Deal value $1.2B
- Deal type Acquisition/Merger
- Therapeutic area Oncology
- Indications Multiple cancers
- Key assets XTEN platform, Pro-HLE IL-2, Pro-HLE IL-15, T-cell engagers
- Mechanism T-cell engager, Protease-activated pro-cytokine (XTEN)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals